Edit Mode Click any text to edit · Click images to replace Saving…

Site Editor

Sign in to edit the website content.

Kraków, Poland · Independent Research Group · Privately Funded

The science of peptides.
For younger lives.

IG Peptides is a privately funded, independent research group based in Kraków, Poland, dedicated to rigorously investigating the physiological effects of bioactive peptides on younger individuals. We are working toward our first comprehensive peer-reviewed study, targeting publication by the end of 2027.

Research Roadmap About IG Peptides
2025
Founded
2027
Study Target
12
Researchers
4
Focus Areas
N C O C N H H O Bioactive Peptide — Reference Structure

Amino Acid Structure — Reference Model

IG Peptides Research Library · Kraków, 2025

About IG Peptides

An Interessengemeinschaft —
what does that mean?

IG Peptides — short for Interest Group for Peptide Research — is a privately funded, independent, non-commercial research group. Rather than a single institution, we are a collective of researchers, clinicians, and biochemists united around one shared scientific question: how do bioactive peptides affect younger individuals?

We are based in Kraków, Poland — a deliberate choice. Poland has one of Europe's most active and open peptide research communities. Unlike more restrictive regulatory environments in Western Europe, Poland allows researchers to work with a wider range of compounds in a controlled academic setting, enabling the kind of comprehensive study design we need to produce meaningful data.

Founded in early 2025 and entirely privately funded, our goal is simple: to produce one rigorous, peer-reviewed study on the physiological effects of peptides in individuals aged 18–35, and have it published before the end of 2027.

IG Peptides operates independently from commercial interests. We do not accept industry funding that could bias our conclusions. We are guided by a shared ethics charter aligned with European academic standards.

Independence

No commercial ties

Our conclusions are shaped by the science alone — not by sponsors or industry interests.

Transparency

Open protocol

Our study design and statistical plan are pre-registered publicly before data collection begins.

Rigour

Peer-review ready

Methodology meets the standards required for indexed academic journal submission.

Ethics

Ethics board oversight

All participant research is reviewed by an independent ethics committee before it begins.

Preliminary Age Cohort Data 18–20 21–23 24–26 27–29 30–32 33–35 35+ IG Peptides Research · Kraków Preliminary concept data · 2025
Research Focus

What we're investigating

Bioactive peptides influence a wide range of physiological processes — yet their effects on younger individuals remain largely unstudied. These are our four core areas of investigation.

Area 01

Hormonal Interaction

How do specific peptide classes interact with growth hormone axes and androgen signalling in individuals aged 18–35, where physiological development and adaptation differ substantially from older adult baselines? We map these responses carefully.

Area 02

Immune Modulation

Immunopeptides hold significant potential during the developmental window of early adulthood. Our research documents dose-dependent and temporal immune responses in younger cohorts under controlled conditions.

Area 03

Metabolic & Recovery

We quantify the metabolic effects of peptide protocols on muscle tissue turnover, recovery markers, and energy metabolism in physically active young individuals — filling a gap that limits practitioner guidance today.

Area 04

Safety & Bioavailability

We track pharmacokinetics, adverse event profiles, and long-term tolerability in our study population — producing safety and bioavailability data that is currently largely absent for this age group in published literature.

Research Roadmap

From formation to publication

IG Peptides is currently active in Phase 1. Each phase builds the foundation required for a rigorous, peer-reviewable outcome by end of 2027.

2025
Active now
Foundation & Protocol Design

In our founding year, IG Peptides is establishing the institutional framework, recruiting core researchers, and conducting a systematic review of existing peptide research in younger populations. We are designing the study protocol, defining inclusion and exclusion criteria, and initiating ethics board applications. Our analytical laboratory in Kraków is being set up and validated.

Group formation Literature review Protocol design Ethics application Lab setup, Kraków
2026
Planned
Data Collection & Analysis

Following ethics approval, we will begin formal participant recruitment. Biomarker baselines will be established, defined peptide protocols administered under controlled conditions, and longitudinal physiological data collected at multiple intervals. A double-blind, placebo-controlled design is used where methodologically appropriate.

Ethics approval Participant recruitment Biomarker baselines Controlled protocols Longitudinal analysis
2027
Target
Manuscript & Publication

Our team will complete statistical analysis, compile results, and author the study manuscript. Target submission to a peer-reviewed journal is Q3 2027, with publication before year-end. All underlying data will be made available in an open-access repository to support reproducibility and further research.

Statistical analysis Manuscript authoring Peer review submission Open data release
2027

Publication target

By the close of 2027, IG Peptides aims to publish the first comprehensive, peer-reviewed study on the physiological effects of bioactive peptides in individuals aged 18–35 — providing a rigorous, privately funded evidence base for researchers, practitioners, and regulators across Europe.

Our Approach

Methodology

1
Systematic Literature Review

A PRISMA-compliant review of existing peptide research identifies gaps and methodological weaknesses in studies involving younger cohorts, forming the foundation for all design decisions.

2
Controlled Participant Cohort

Participants aged 18–35 are recruited under ethics-approved inclusion/exclusion criteria. A double-blind, placebo-controlled design minimises bias wherever methodologically appropriate.

3
Multi-Biomarker Analysis

Blood plasma and urinary markers are collected at defined intervals using validated LC-MS/MS and ELISA assays. Functional performance data supplements the biochemical picture.

4
Pre-Registered Statistical Plan

Primary and secondary endpoints and the full analysis plan are pre-registered with OSF before data collection begins — preventing post-hoc hypothesis adjustment and ensuring full credibility.

Step 01 Participant Selection · Ages 18–35 Ethics-approved · Informed consent Step 02 Biomarker Baseline Measurement Blood plasma · Urinary markers · Performance Group A Peptide Protocol Defined dosage · Monitored Group B Placebo Control Blinded · Parallel design Step 04 Statistical Analysis · Pre-Registered LC-MS/MS · ELISA · OSF pre-registration Target: Q4 2027 Peer-Reviewed Publication
The Group

Core research team

Four specialists at the core. Additional associate researchers and external advisors contribute on a project basis.

Markus Kellenberger
Lead Researcher & Founder

Biochemist specialising in peptide synthesis and bioavailability. 18 years of experience in private and academic laboratory environments across Central Europe.

Isabelle Fontaine
Study Design & Analytics

Sports physiologist and clinical researcher. Expertise in cohort design, biostatistics, and participant monitoring protocols. Previously based in Lausanne.

Raj Subramaniam
Analytical Chemistry

Expert in mass spectrometry and chromatographic analysis of peptide compounds. Responsible for establishing IG Peptides' analytical platform in Kraków.

Elena Marchetti
Ethics & Clinical Oversight

Medical doctor with a background in paediatric health and clinical trial coordination. Liaison to the independent ethics review board.

Get Involved

Interested in our research?

We are looking for qualified study participants aged 18–35, scientific advisors, and potential collaborators. Formal recruitment begins in 2026 — register your interest now.

Contact the team
Contact

Get in touch

We welcome scientific enquiries

Whether you are a researcher, clinician, potential study participant, or journalist — we are happy to share more about our work and upcoming study.

[email protected]
+41  78 206 50 32
ul. Bobrzyńskiego 14, 30-348 Kraków, Poland
Monday – Friday, 09:00 – 17:00 CET
Study Participation

If you are aged 18–35 and interested in participating in our upcoming study, formal recruitment begins in 2026. You may register your interest now via the contact form.

Send a message